Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Christopher McNair, PhD, on Decreases in Cancer-Related Care Due to COVID-19

August 13, 2020
By Hannah Slater
Video

A study published in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients being seen for cancer-related care due to the COVID-19 pandemic.

Researchers from the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) found significant decreases nationwide in the number of patients being seen for cancer-related care as a result of the coronavirus disease 2019 (COVID-19).

The study, published in JCO Clinical Cancer Informatics, found the most significant decline in encounters to be those related to new cancer incidences, including screening, initial diagnosis, second opinion, and treatment initiation appointments.

“The COVID-19 pandemic has had a tremendous immediate impact on the world, and it is clear that there will be effects for years to come,” the authors wrote. “Ultimately, these observed trends have serious implications for future cancer care and validate the need to study and monitor the effect of COVID-19 mitigation on cancer diagnosis and treatment moving forward.

In an interview with CancerNetwork®, Christopher McNair, PhD, director of Cancer Informatics and assistant professor in the Department of Cancer Biology at SKCC, discussed the study findings and the possible future implications for patients with cancer should these trends continue.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. JCO Clinical Cancer Informatics. doi: 10.1200/CCI.20.00068

Recent Videos
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Advertisement

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

Roman Fabbricatore
July 23rd 2025
Article

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Ariana Pelosci
July 23rd 2025
Article

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

Tim Cortese
July 23rd 2025
Article

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.


The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Tim Cortese
July 22nd 2025
Article

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Related Content
Advertisement

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

Roman Fabbricatore
July 23rd 2025
Article

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Ariana Pelosci
July 23rd 2025
Article

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

Tim Cortese
July 23rd 2025
Article

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.


The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Tim Cortese
July 22nd 2025
Article

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.